Clinical Trials Logo
  1. Home
  2. Oncology
  3. NCT02356822
  4. Details
NCT02356822 Clinical Trial

Sarah Cannon Outcomes Registry

Oncology Clinical Trial

Official title:
Sarah Cannon Outcomes Registry

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT02356822
Other study ID # SCRI HEOR_01
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date December 2014
Est. completion date December 2024

Study information
Verified date June 2019
Source SCRI Development Innovations, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This is an investigational multi-site outcomes registry intended to collect information about a patient's cancer care. Patients may enter the Registry at any time during the patient's current stage in the continuum of care. The registries main objectives will be to measure and evaluate the effects of patient care throughout the care continuum, resulting in the identification of the most effective treatment options. Objectives will encompass evaluations and analytics around safety, effectiveness, and improved efficiencies.

Description:

Q

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date December 2024
Est. primary completion date December 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 or older - Patients that have been diagnosed with/ or are thought to have any form of cancer at any stage in the continuum of their care from screening through survivorship. - Patient must have the ability to understand the nature of the trial and give written informed consent Exclusion Criteria: - There are no exclusion criteria for this Outcomes Registry

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Patient registry
Oncology data registry

Locations
Country Name City State
United States SCRI Nashville Tennessee

Sponsors (1)
Lead Sponsor Collaborator
SCRI Development Innovations, LLC

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Other safety and effectiveness 10 yrs
Primary quality improvement 10 yrs
Primary Treatment patterns and utilization 5 yrs
Secondary Humanistic and economic outcomes 10 yrs
See also
  Status Clinical Trial Phase
Completed NCT01439152 - Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. Phase 1
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Active, not recruiting NCT06015009 - Symptom Management App for Children at the Early Stage of Cancer Survivorship and Their Caregivers N/A
Active, not recruiting NCT03298100 - Risk Scoring Model for Endometrial Cancer
Recruiting NCT05055609 - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors Phase 1
Not yet recruiting NCT04324320 - Psychological Distress in Outpatient Oncological Rehabilitation
Completed NCT00588289 - Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA N/A
Recruiting NCT06222801 - The 1st Tumor CytokinoTherapy Database (TCTD-1)
Recruiting NCT03831633 - Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients Phase 4
Completed NCT04914702 - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Recruiting NCT05198570 - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Recruiting NCT05712174 - A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer Phase 2
Recruiting NCT03832062 - Value of Analysing Under-utilised Leftover Tissue (VauLT)
Completed NCT03988777 - Magnetic Seed Localisation for Nonpalpable Breast Lesions
Recruiting NCT06031233 - Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie Phase 4
Enrolling by invitation NCT04019119 - Digital Intervention for the Modification of Lifestyles (iGame) N/A
Not yet recruiting NCT05926362 - Capillary-Venous Paired Data Collection
Recruiting NCT05510856 - Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients Phase 4
Recruiting NCT05686213 - ExeNTrO: Exercise During Neoadjuvant Chemoradiation Treatment to Improve Rectal and Esophageal Cancer Outcome - Pilot Trial Phase 2
Completed NCT04180306 - PEWS Implementation in an LMIC Setting N/A